CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, is highlighting the recent European Heart Journal publication of SCD-PROTECT, an independent clinical trial designed to specifically evaluate the risk of sudden cardiac death (SCD) in the early post-MI/CAD and new NICM period with four-pillar guideline-directed medical therapy (GDMT). Key findings across 19,598 consecutive LifeVest WCD patients:1 There was very hig